Biotech leaders often assume that buying a SIEM, adding endpoint protection, and assigning alerts to the internal IT team creates a functioning security operation.
It does not. It’s not even close to meeting the minimum threshold.
It creates visibility. Visibility matters, but visibility without dedicated investigation, response authority, and after-hours coverage only tells you that something may be wrong. It does not guarantee that anyone will act before the problem reaches research systems, intellectual property, laboratory operations, or executive leadership.
For biotech companies under $100 million in revenue, this is a dangerous gap. The company may have invested in capable technology while underfunding the people and operating capacity required to use it.
The result is not a tool failure. It is an accountability failure.
Leadership Assigned a 24×7 Job to a Business-Hours Team
Most internal IT teams are not ignoring security. They are overloaded. Most internal IT teams are working business hours.
They manage cloud environments, identity platforms, endpoints, vendors, backups, user support, compliance requests, laboratory systems, and infrastructure changes. Security monitoring is added to the same queue, often without dedicated analysts, overnight staffing, documented escalation paths, or authority to contain threats immediately.
An alert generated at 2:13 a.m. may be technically visible while remaining operationally unattended.
It may involve a suspicious login, privileged account misuse, unusual data movement, malware execution, or a compromised third-party account. The company can claim that it has monitoring. But the more important question is whether anyone is required to acknowledge, investigate, and escalate that alert within a defined period.
If the answer depends on who sees an email, checks a dashboard, or recognizes the severity, the organization does not have 24×7 security operations. It has 24×7 alert generation. Those are not the same thing.
The Business Risk Is Larger Than the Alert
In biotech, delayed response rarely affects only one endpoint.
A compromised identity can expose research data, collaboration platforms, clinical documentation, investor materials, or intellectual property stored across cloud applications. Malware on a researcher’s device can interrupt experiments, shared drives, or specialized software. An attacker using legitimate credentials may remain undetected because the activity does not initially look destructive.
The longer investigation is delayed, the more expensive the incident becomes.
Research teams may lose access to systems. Legal counsel may need to determine whether confidential or regulated information was exposed. Executives may have to explain the incident to investors, partners, or the board.
For a growth-stage biotech company, that can affect credibility, funding conversations, and valuation.
Investors do not expect leadership to eliminate every cyber threat. They do expect leadership to know who is accountable when one appears.
A Common Biotech Failure
Consider a familiar scenario.
A biotech company deploys endpoint detection, cloud security tools, and a SIEM. The IT director reviews alerts during the day. After hours, critical notifications are forwarded to a shared mailbox and an on-call phone.
On paper, the environment appears covered.
Then a contractor account is used late at night from an unfamiliar location. The login is followed by access to multiple cloud folders and unusual file downloads. The tools generate separate alerts, but no analyst connects them into one incident until the next morning.
By then, the company is no longer asking whether the login was suspicious. It is asking what data was accessed, whether files left the environment, whether credentials were reused, and whether research activity must be interrupted.
The technology worked. The operating model failed.
Managed Security Is Not Surrendering Control
Some leaders resist managed security because they believe it means admitting the internal team is incapable. That is narrow thinking.
Managed security should not replace internal leadership. It should provide the operating capacity the company has not built internally: continuous monitoring, experienced investigation, guaranteed acknowledgement times, escalation discipline, documented response procedures, and after-hours coverage.
A strong managed or co-managed model lets the internal team retain business context and strategic control. The provider adds dedicated analysts and repeatable processes when the team is handling other priorities or is offline.
That is not a shortcut. It is a deliberate division of responsibility.
The internal team knows the business. The managed security team maintains the watch.
What Directors and CISOs Should Evaluate
Before buying another platform, leadership should answer these questions:
- Who is watching alerts after hours?
- How quickly must a critical alert be acknowledged and investigated?
- Who can isolate an endpoint, disable an account, or block suspicious access?
- Can analysts see endpoint, identity, cloud, network, and third-party activity in context?
- Are escalation procedures documented and tested?
- Can the company prove that monitoring and response operate continuously?
- Does the internal team have enough time to improve controls and prepare for incidents?
If these answers are unclear, more technology will create more alerts without solving the problem.
The Decision Leadership Must Make
The real choice is not between SIEM, MDR, and SOC terminology.
The choice is whether the company will continue placing 24×7 accountability on an underfunded team or build an operating model with the staffing, expertise, authority, and response commitments required to support the business.
A security assessment should test endpoint and identity visibility, cloud monitoring, after-hours response, containment authority, backup readiness, vulnerability management, escalation, and incident-response maturity.
That assessment may confirm that the current model is sufficient. It may also reveal that the company owns more technology than operational protection.
As the company grows, the number of identities, vendors, research systems, cloud platforms, and sensitive data sources will grow with it.
The question is not whether the tools can generate alerts.
The question is whether the current team can investigate and act fast enough when the business is depending on them.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
